Filtered By:
Condition: Heart Valve Disease
Education: Study

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 330 results found since Jan 2013.

10-year results of On-X bileaflet mechanical heart valve in the aortic position: low target INR regimen in Japanese
ConclusionsAVR using On-X valve with low target INR regimen and low-dose aspirin resulted in a significantly low risk of bleeding.
Source: General Thoracic and Cardiovascular Surgery - April 19, 2017 Category: Cardiovascular & Thoracic Surgery Source Type: research

Ischemic Optic Neuropathy in Cardiac Surgery Incidence and Risk Factors in the United States from the National Inpatient Sample 1998 to 2013
Conclusions The incidence of ischemic optic neuropathy in cardiac surgery did not change during the study period. Development of ischemic optic neuropathy after cardiac surgery is associated with carotid artery stenosis, stroke, and degenerative eye conditions.
Source: Anesthesiology - April 18, 2017 Category: Anesthesiology Source Type: research

Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis: Insights From the Valve-in-Valve International Data Registry (VIVID) Structural Heart Disease
Conclusions— In this first matched comparison of THVs for valve-in-valve implantations, Portico and CoreValve demonstrated differences in postprocedural hemodynamics and long-term clinical outcomes. Although this could be related to THV design characteristics, the impact of other procedural factors cannot be excluded and require further evaluation.
Source: Circulation: Cardiovascular Interventions - April 11, 2017 Category: Cardiology Authors: Alnasser, S., Cheema, A. N., Simonato, M., Barbanti, M., Edwards, J., Kornowski, R., Horlick, E., Wijeysundera, H. C., Testa, L., Bedogni, F., Amrane, H., Walther, T., Pelletier, M., Latib, A., Laborde, J.-C., Hildick-Smith, D., Kim, W.-K., Tchetche, D., Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research

Medtronic wins FDA nod for CoreValve Evolut Pro
Medtronic (NYSE:MDT) said today it won FDA approval for its CoreValve Evolut Pro transcatheter arortic heart valve replacement designed for treating severe aortic stensosis. The newly cleared, next-gen CoreValve Evolut Pro features an outer wrap to add surface area contact between the valve and the native aortic annulus to increase valve sealing performance, Fridley, Minn.-based Medtronic said. “Medtronic remains committed to working with interventional cardiologists and cardiac surgeons to deliver solutions that address patient needs with the safety and performance profile they expect from Medtronic. We are excited ...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

ACC 2017 Roundup: Medtronic ’ s CoreValve as good as surgery in intermediate-risk trial
The team at MassDevice.com and Drug Delivery Business News will be updating this post periodically as news comes out of ACC 2017, the annual American College of Cardiology meeting in Washington March 17-19. Medtronic’s CoreValve as good as surgery in intermediate-risk trial A study comparing surgical valve replacement with transcatheter aortic valve replacement using the CoreValve device made by Medtronic (NYSE:MDT) showed that the TAVR device was as safe as surgery in intermediate-risk patients, according to data presented today at ACC 2017. Two-year data from the 1,657-patient Surtavi study, presented at ACC 2017 a...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Replacement Heart Valves ACC 2017 Medtronic Source Type: news

Direct percutaneous transaxillary implantation of a novel self ‐expandable transcatheter heart valve for aortic stenosis
ConclusionsOur study suggests that the implantation of the second‐generation self‐expandable ACURATE Neo™ via a transaxillary access is technically feasible and safe and yields excellent short‐term clinical results. © 2017 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - March 14, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Florian Deuschl, Niklas Schofer, Moritz Seiffert, Samer Hakmi, Isamu Mizote, Andreas Schaefer, Johannes Schirmer, Hermann Reichenspurner, Stefan Blankenberg, Lenard Conradi, Ulrich Sch äfer Tags: Valvular and Structural Heart Diseases Source Type: research

Keystone Heart, Venus Medtech ink Asian TAVR stroke partnership deal
Keystone Heart and Chinese heart valve maker Venus Medtech said today they inked a partnership deal covering China and other Asian markets. Through the deal, the companies will provide Venus Medtech’s transcatheter aortic valve replacement system along with Keystone’s TriGuard cerebral embolic protection device. TriGuard is a cerebral embolic protection device designed to reduce the amount of embolic material entering blood circulation to the brain during TAVR procedures, by allowing blood to pass through while catching potentially dangerous embolic debris. “Providing brain protection for every TAVR pat...
Source: Mass Device - March 2, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Replacement Heart Valves Keystone Heart Venus Medtech Source Type: news

Boston Scientific touts no deaths, low PVL rates in Lotus TAVR trial
Boston Scientific (NYSE:BSX) this week presented new data from the Respond extension study of its Lotus transcatheter aortic valve replacement with its Depth Guard technology, touting no deaths and low rates of paravalvular regurgitation. Data from the study was presented at the Cardiovascular Research Technologies CRT 2017 annual meeting in Washington D.C. The 50-patient Respond Extension study aimed to assess clinical and device performance outcomes with its Lotus Valve in combination with the Depth Guard technology. The Marlborough, Mass.-based company’s Depth Guard tech is designed to optimize valve deployment by an...
Source: Mass Device - February 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Boston Scientific Source Type: news

SOURCE 3 Registry: Design and 30-Day Results of the European Post Approval Registry of the Latest Generation of the Sapien 3TM Transcatheter Heart Valve.
CONCLUSIONS: -Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when using this third generation TAVI device. PMID: 28104716 [PubMed - as supplied by publisher]
Source: Circulation - January 18, 2017 Category: Cardiology Authors: Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Ihlberg L, Neumann FJ, Tarantini G, Zamorano JL, Vahanian A Tags: Circulation Source Type: research

Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis.
CONCLUSIONS: The present study was the first to demonstrate a significant relationship between increased serum VAP-1 levels and the severity of calcific AS. VAP-1 might be a useful biomarker for the evaluation of AS and the follow up of its severity. PMID: 27997774 [PubMed]
Source: Journal of Heart Valve Disease - December 22, 2016 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Aortic Valve Replacement in Redo-Scenarios: A Comparison Between Traditional Aortic Valve Replacement (TAVR) and Transapical-TAVR from Two Real-World Multicenter Registries.
CONCLUSIONS: Outcome differences between RAVR and TaTAVR in redo-scenarios reflect methodological differences and different baseline risk profiles. Propensity-matched patients showed a better renal outcome after TaTAVR. *Drs. Onorati and D'Onofrio contributed equally to this article and should both be considered as first authors. PMID: 27997769 [PubMed]
Source: Journal of Heart Valve Disease - December 22, 2016 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
CONCLUSIONS: Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival. PMID: 27989055 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 21, 2016 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Quantitative Doppler for Estimation of Paravalvular Leakage after Transcatheter Aortic Valve Implantation.
CONCLUSIONS: The relationship between calculated PVL volume in TAVI patients and other estimates of PVL severity was poor, most likely due to intrinsic errors made in the quantitative Doppler method. Therefore, one should be prudent to include the quantitative Doppler method in TAVI patients in clinical trials and clinical decision-making, in particular in patients with reduced image quality. PMID: 27989038 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 21, 2016 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis ADULT CARDIAC
CONCLUSIONS In a high-risk cohort of patients undergoing TA-TAVR for AS, the use of the JenaValve THV is safe and effective. In patients at higher risk for coronary ostia obstruction, annular rupture or with limited aortic valve calcification, the JenaValve might be preferable for implantation due to its clipping-mechanism engaging native aortic valve cusps for fixation with reduced radial forces of the self-expanding stent.
Source: European Journal of Cardio-Thoracic Surgery - November 3, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Silaschi, M., Treede, H., Rastan, A. J., Baumbach, H., Beyersdorf, F., Kappert, U., Eichinger, W., Rüter, F., de Kroon, T. L., Lange, R., Ensminger, S., Wendler, O. Tags: History, Basic research vascular ADULT CARDIAC Source Type: research

Direct Oral Anticoagulants in Emergency Trauma Admissions.
CONCLUSION: DOACs in the setting of hemorrhage are a clinical challenge in the traumatological emergency room because of the inadequate validity of the relevant laboratory tests. An emergency antidote is now available only for dabigatran. PMID: 27658470 [PubMed - in process]
Source: Deutsches Arzteblatt International - September 24, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research